Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

Abstract Lymphangioleiomyomatosis (LAM) is a rare disease involving cystic lung destruction by invasive LAM cells. These cells harbor loss‐of‐function mutations in TSC2, conferring hyperactive mTORC1 signaling. Here, tissue engineering tools are employed to model LAM and identify new therapeutic can...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Adam Pietrobon, Julien Yockell‐Lelièvre, Nicole Melong, Laura J. Smith, Sean P. Delaney, Nadine Azzam, Chang Xue, Nishanth Merwin, Eric Lian, Alberto Camacho‐Magallanes, Carole Doré, Gabriel Musso, Lisa M. Julian, Arnold S. Kristof, Roger Y. Tam, Jason N. Berman, Molly S. Shoichet, William L. Stanford
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2023-09-01
Σειρά:	Advanced Science
Θέματα:	3D drug screen biomimetic hydrogel culture HDAC inhibition lymphangioleiomyomatosis mTORC1 therapeutics development
Διαθέσιμο Online:	https://doi.org/10.1002/advs.202302611
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!